New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials.
about
Antibiotic-free selection in biotherapeutics: now and foreverProteomic profiling of salivary gland after nonviral gene transfer mediated by conventional plasmids and minicircles.Minicircle Mediated Gene Delivery to Canine and Equine Mesenchymal Stem Cells.Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis.Correction of Diabetic Hyperglycemia and Amelioration of Metabolic Anomalies by Minicircle DNA Mediated Glucose-Dependent Hepatic Insulin Production.Production and characterization of novel recombinant adeno-associated virus replicative-form genomes: a eukaryotic source of DNA for gene transfer.FabV/Triclosan Is an Antibiotic-Free and Cost-Effective Selection System for Efficient Maintenance of High and Medium-Copy Number Plasmids in Escherichia coli.Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.Use of FabV-Triclosan Plasmid Selection System for Efficient Expression and Production of Recombinant Proteins in Escherichia coliEfficient sleeping beauty DNA transposition from DNA minicircles.New technologies in developing recombinant attenuated Salmonella vaccine vectors.Antibiotic free selection for the high level biosynthesis of a silk-elastin-like protein.Use of Staby(®) technology for development and production of DNA vaccines free of antibiotic resistance gene.Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression.Advances in Non-Viral DNA Vectors for Gene Therapy.Toxin-antitoxin systems are ubiquitous and versatile modulators of prokaryotic cell fate.Applying horizontal gene transfer phenomena to enhance non-viral gene therapyClinical potential of electroporation for gene therapy and DNA vaccine delivery.State of play and clinical prospects of antibody gene transfer.Expression Changes in Metal-Resistance Genes in Microbacterium liquefaciens Under Nickel and Vanadium Exposure.Enhanced gene disruption by programmable nucleases delivered by a minicircle vector.Design and Construction of Shrimp Antiviral DNA Vaccines Expressing Long and Short Hairpins for Protection by RNA Interference.Development of an antibiotic marker-free platform for heterologous protein production in StreptomycesVariola type IB DNA topoisomerase: DNA binding and supercoil unwinding using engineered DNA minicircles.Gene Electrotransfer of Canine Interleukin 12 into Canine Melanoma Cell Lines.Live Bacterial Vectors-A Promising DNA Vaccine Delivery System.Identification of Bacillus megaterium and Microbacterium liquefaciens genes involved in metal resistance and metal removal.Clinically Usable Interleukin 12 Plasmid without an Antibiotic Resistance Gene: Functionality and Toxicity Study in Murine Melanoma Model.The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells.Selection by RNA-RNA Interaction: Maximally Minimized Antibiotic Resistance-Free Plasmids
P2860
Q27028105-3BFC9308-B7E2-4015-970A-75B832E97015Q30425855-FDE4B55B-7526-4E93-9C9B-45B5E628F919Q33624730-A2F8E93A-658D-4C81-B1DB-A5F5C1B1A861Q33650357-02D3A37C-F100-43EE-8DA3-8AA5EB6C97F0Q34797310-06A60EB2-73DB-4A18-BE5A-BE40AAA95B57Q34924696-69DCC0B3-14F9-4497-B536-DC2E546FF887Q35657979-4F58FB9A-D682-43ED-A592-3ADBF7683B54Q35826665-E1D8469F-1F95-477F-93AB-9B35BF2059B4Q35862599-54AA7208-F723-4370-8319-50ACE4A13837Q36652377-9769B8F7-1B63-4E16-9FD4-6A09A211BA3FQ36653379-BD40B254-E079-49A8-9700-F171BFDE4CBAQ37508311-EC07E4F7-D410-48F0-B028-A68650752BB7Q37530516-13F93C2E-4A89-442E-A9CF-9F57628C6221Q37541745-E29CB7A6-C4B7-4FA5-BE16-A4FBE1F0E89EQ37676243-0607ED12-C010-46B6-A6AB-A70FE14C36D4Q38071667-1CA5EA46-D723-448C-B840-CD1B08A1B4CCQ38133156-C52C3BB8-EAF1-421F-94C8-129D1323F706Q38636510-4A756068-4E8B-4EC9-85AC-C1680975EA4BQ38737706-95DCB4F1-7247-4E4C-AC53-ACCD6C0EFFCEQ38817796-4C554946-C58C-45C3-B8EE-0BCCDFDAC0AFQ38964283-44E542DA-4730-4FFB-B67A-66EFAD3E80D2Q40801639-7F3AB6B4-EA15-4EE4-BB26-A65896B72B59Q41676350-C59AEE16-8094-486D-B74B-742F6742977DQ42211325-4D81C6F3-36D6-49EC-A743-6D1E79ED3B1EQ45874636-914C9006-9895-470B-BB3E-FFF0AA3A08EFQ52640510-5C43CA18-0D62-499D-BD13-797936338CACQ53094850-1C59B5E6-0FFB-48BC-8639-02CD71BC7BA2Q53705456-B5CEF191-797D-4F1F-9073-5C16C5E21F8AQ55365935-7B2CC134-BA35-40C0-A37F-0250938E648DQ58840785-CC97E10A-6E62-4091-96CA-A87568CCC17A
P2860
New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New generation of plasmid back ...... arker for gene therapy trials.
@en
New generation of plasmid back ...... arker for gene therapy trials.
@nl
type
label
New generation of plasmid back ...... arker for gene therapy trials.
@en
New generation of plasmid back ...... arker for gene therapy trials.
@nl
prefLabel
New generation of plasmid back ...... arker for gene therapy trials.
@en
New generation of plasmid back ...... arker for gene therapy trials.
@nl
P2093
P2860
P356
P1433
P1476
New generation of plasmid back ...... arker for gene therapy trials.
@en
P2093
Corinne Marie
Daniel Scherman
Véronique Préat
P2860
P304
P356
10.1038/MT.2011.182
P577
2011-08-30T00:00:00Z